Figure 1

Flow diagram illustrating the study selection process. Between 2017 and 2018, we identified 226 patients, who received hybrid ¹⁸F-FET PET/cMRI. According to the eligibility criteria, a total of 42 patients with glioma recurrence in question were included into our retrospective study.